Prof. Dr. Jens Huober
Chefarzt/Chefärztin
Brustzentrum St.Gallen, Medizinische Onkologie und Hämatologie · Dept. IV, Dept. I
Therapy Landscape in Patients with Metastatic HER2-Positive Breast Cancer: Data from the PRAEGNANT Real-World Breast Cancer Registry
Lux M, Wimberger P, Hielscher C, Geberth M, Abenhardt W, Kurbacher C, Wuerstlein R, Thomssen C, Untch M, Fasching P, Janni W, Fehm T, Wallwiener D, Schneeweiss A, Belleville E, Beckmann M, Müller V, Nabieva N, Hartkopf A, Huober J, Volz B, Taran F, Overkamp F, Kolberg H, Hadji P, Tesch H, Häberle L, Ettl J, Luftner D, Wallwiener M, Brucker S. Therapy Landscape in Patients with Metastatic HER2-Positive Breast Cancer: Data from the PRAEGNANT Real-World Breast Cancer Registry. Cancers (Basel) 2018; 11
21.12.2018Therapy Landscape in Patients with Metastatic HER2-Positive Breast Cancer: Data from the PRAEGNANT Real-World Breast Cancer Registry
21.12.2018Cancers (Basel) 2018; 11
Lux Michael P, Wimberger Pauline, Hielscher Carsten, Geberth Matthias, Abenhardt Wolfgang, Kurbacher Christian, Wuerstlein Rachel, Thomssen Christoph, Untch Michael, Fasching Peter A, Janni Wolfgang, Fehm Tanja N, Wallwiener Diethelm, Schneeweiss Andreas, Belleville Erik, Beckmann Matthias W, Müller Volkmar, Nabieva Naiba, Hartkopf Andreas D, Huober Jens, Volz Bernhard, Taran Florin-Andrei, Overkamp Friedrich, Kolberg Hans-Christian, Hadji Peyman, Tesch Hans, Häberle Lothar, Ettl Johannes, Luftner Diana, Wallwiener Markus, Brucker Sara Y
Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOcto-GBG 84): A randomised phase III trial
Schneeweiss A, Ingold-Heppner B, Blohmer J, Rezai M, Frank M, Engels K, Rhiem K, Fasching P, Nekljudova V, von Minckwitz G, Thomalla J, Jackisch C, Kast K, Möbus V, Tesch H, Hanusch C, Denkert C, Lübbe K, Huober J, Klare P, Kümmel S, Untch M, Loibl S. Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOcto-GBG 84): A randomised phase III trial. Eur J Cancer 2018; 106:181-192.
05.12.2018Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOcto-GBG 84): A randomised phase III trial
05.12.2018Eur J Cancer 2018; 106:181-192
Schneeweiss Andreas, Ingold-Heppner Barbara, Blohmer Jens-Uwe, Rezai Mahdi, Frank Matthias, Engels Knut, Rhiem Kerstin, Fasching Peter Andreas, Nekljudova Valentina, von Minckwitz Gunter, Thomalla Jörg, Jackisch Christian, Kast Karin, Möbus Volker, Tesch Hans, Hanusch Claus, Denkert Carsten, Lübbe Kristina, Huober Jens, Klare Peter, Kümmel Sherko, Untch Michael, Loibl Sibylle
Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032/045OL, December 2017) - Part 2 with Recommendations for the Therapy of Primary, Recurrent and Advanced Breast Cancer
Bjelic-Radisic V, Dunst J, Münstedt K, Bick U, Fallenberg E, Tholen R, Hung R, Baumann F, Beckmann M, Blohmer J, Fasching P, Sinn H, Hirsmüller S, Degenhardt F, Wenz F, Rick O, Hölzel D, Zaiss M, Kemper G, Budach V, Denkert C, Gerber B, Tesch H, Lux M, Harbeck N, Schmidt M, Schmutzler R, Schneeweiss A, Schütz F, Stickeler E, Thomssen C, Untch M, Wesselmann S, Bücker A, Buck A, Nöthlings U, Müller V, Hadji P, Hauner H, Heywang-Köbrunner S, Huober J, Hübner J, Jackisch C, Loibl S, Lück H, von Minckwitz G, Möbus V, Stangl S, Paradies K, Wöckel A, Kühn T, Langer T, Nothacker M, Scharl A, Schreer I, Link H, Engel J, Fehm T, Weis J, Welt A, Kreienberg R, Kopp I, Festl J, Stüber T, Brust K, Krockenberger M, Heuschmann P, Jírů-Hillmann S, Albert U, Budach W, Follmann M, Janni W, Steckelberg A, Feyer P, Petersen C, Bartsch H, Schulz-Wendtland R, Hahn M, Hanf V, Müller-Schimpfle M, Henscher U, Roncarati R, Katalinic A, Heitmann C, Siedentopf F, Lebeau A, König K, Hahne A, Baumgartner T, Kreipe H, Knoefel W, Denkinger M, Brucker S, Luftner D, Kubisch C, Gerlach C, Honegger C. Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032/045OL, December 2017) - Part 2 with Recommendations for the Therapy of Primary, Recurrent and Advanced Breast Cancer. Geburtshilfe Frauenheilkd 2018; 78:1056-1088.
26.11.2018Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032/045OL, December 2017) - Part 2 with Recommendations for the Therapy of Primary, Recurrent and Advanced Breast Cancer
26.11.2018Geburtshilfe Frauenheilkd 2018; 78:1056-1088
Bjelic-Radisic Vesna, Dunst Jürgen, Münstedt Karsten, Bick Ulrich, Fallenberg Eva, Tholen Reina, Hung Roswita, Baumann Freerk, Beckmann Matthias W, Blohmer Jens, Fasching Peter, Sinn Hans-Peter, Hirsmüller Susanne, Degenhardt Friedrich, Wenz Frederik, Rick Oliver, Hölzel Dieter, Zaiss Matthias, Kemper Gudrun, Budach Volker, Denkert Carsten, Gerber Bernd, Tesch Hans, Lux Michael P, Harbeck Nadia, Schmidt Marcus, Schmutzler Rita, Schneeweiss Andreas, Schütz Florian, Stickeler Elmar, Thomssen Christoph, Untch Michael, Wesselmann Simone, Bücker Arno, Buck Andreas, Nöthlings Ute, Müller Volkmar, Hadji Peyman, Hauner Hans, Heywang-Köbrunner Sylvia, Huober Jens, Hübner Jutta, Jackisch Christian, Loibl Sibylle, Lück Hans-Jürgen, von Minckwitz Gunter, Möbus Volker, Stangl Stephanie, Paradies Kerstin, Wöckel Achim, Kühn Thorsten, Langer Thomas, Nothacker Monika, Scharl Anton, Schreer Ingrid, Link Hartmut, Engel Jutta, Fehm Tanja, Weis Joachim, Welt Anja, Kreienberg Rolf, Kopp Ina, Festl Jasmin, Stüber Tanja, Brust Katharina, Krockenberger Mathias, Heuschmann Peter U, Jírů-Hillmann Steffi, Albert Ute-Susann, Budach Wilfried, Follmann Markus, Janni Wolfgang, Steckelberg Anke, Feyer Petra, Petersen Cordula, Bartsch Hans Helge, Schulz-Wendtland Rüdiger, Hahn Markus, Hanf Volker, Müller-Schimpfle Markus, Henscher Ulla, Roncarati Renza, Katalinic Alexander, Heitmann Christoph, Siedentopf Friederike, Lebeau Annette, König Klaus, Hahne Andrea, Baumgartner Traudl, Kreipe Hans H, Knoefel Wolfram Trudo, Denkinger Michael, Brucker Sara, Luftner Diana, Kubisch Christian, Gerlach Christina, Honegger Christoph
Axillary Surgery in Breast Cancer Patients Treated with Breast-Conserving Surgery at German Breast Cancer Centers Within the Last 14 Years - Comparison of a University Center and a Community Hospital
De Gregorio A, Widschwendter P, Albrecht S, De Gregorio N, Friedl T, Huober J, Janni W, Ebner F. Axillary Surgery in Breast Cancer Patients Treated with Breast-Conserving Surgery at German Breast Cancer Centers Within the Last 14 Years - Comparison of a University Center and a Community Hospital. Geburtshilfe Frauenheilkd 2018; 78:1138-1145.
26.11.2018Axillary Surgery in Breast Cancer Patients Treated with Breast-Conserving Surgery at German Breast Cancer Centers Within the Last 14 Years - Comparison of a University Center and a Community Hospital
26.11.2018Geburtshilfe Frauenheilkd 2018; 78:1138-1145
De Gregorio Amelie, Widschwendter Peter, Albrecht Susanne, De Gregorio Nikolaus, Friedl Thomas W P, Huober Jens, Janni Wolfgang, Ebner Florian K
Association of T-Cell Receptor Repertoire Use With Response to Combined Trastuzumab-Lapatinib Treatment of HER2-Positive Breast Cancer: Secondary Analysis of the NeoALTTO Randomized Clinical Trial
Powles R, Pusztai L, Elemento O, Piccart-Gebhart M, Baselga J, Huober J, Di Cosimo S, Sarp S, de Azambuja E, Harbeck N, Nuciforo P, Fumagalli D, Loi S, Sotiriou C, Redmond D, Hatzis C. Association of T-Cell Receptor Repertoire Use With Response to Combined Trastuzumab-Lapatinib Treatment of HER2-Positive Breast Cancer: Secondary Analysis of the NeoALTTO Randomized Clinical Trial. JAMA Oncol 2018; 4:e181564.
08.11.2018Association of T-Cell Receptor Repertoire Use With Response to Combined Trastuzumab-Lapatinib Treatment of HER2-Positive Breast Cancer: Secondary Analysis of the NeoALTTO Randomized Clinical Trial
08.11.2018JAMA Oncol 2018; 4:e181564
Powles Ryan L, Pusztai Lajos, Elemento Olivier, Piccart-Gebhart Martine, Baselga José, Huober Jens, Di Cosimo Serena, Sarp Severine, de Azambuja Evandro, Harbeck Nadia, Nuciforo Paolo, Fumagalli Debora, Loi Sherene, Sotiriou Christos, Redmond David, Hatzis Christos
Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032/045OL, December 2017) - Part 1 with Recommendations for the Screening, Diagnosis and Therapy of Breast Cancer
Bjelic-Radisic V, Dunst J, Münstedt K, Bick U, Fallenberg E, Tholen R, Hung R, Baumann F, Beckmann M, Blohmer J, Sinn H, Hirsmüller S, Tesch H, Degenhardt F, Wenz F, Rick O, Hölzel D, Zaiss M, Kemper G, Budach V, Denkert C, Gerber B, Fasching P, Lux M, Harbeck N, Schmidt M, Schmutzler R, Schneeweiss A, Schütz F, Stickeler E, Thomssen C, Untch M, Wesselmann S, Bücker A, Nöthlings U, Müller V, Möbus V, Hadji P, Hauner H, Heywang-Köbrunner S, Huober J, Hübner J, Jackisch C, Loibl S, Lück H, von Minckwitz G, Krockenberger M, Wöckel A, Langer T, Nothacker M, Scharl A, Schreer I, Link H, Engel J, Fehm T, Weis J, Welt A, Kühn T, Kreienberg R, Kopp I, Festl J, Stüber T, Brust K, Stangl S, Heuschmann P, Albert U, Budach W, Follmann M, Janni W, Steckelberg A, Feyer P, König K, Schulz-Wendtland R, Hahn M, Hanf V, Müller-Schimpfle M, Henscher U, Roncarati R, Katalinic A, Heitmann C, Honegger C, Bartsch H, Petersen C, Siedentopf F, Hahne A, Kreipe H, Knoefel W, Denkinger M, Brucker S, Luftner D, Kubisch C, Gerlach C, Lebeau A, Paradies K. Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032/045OL, December 2017) - Part 1 with Recommendations for the Screening, Diagnosis and Therapy of Breast Cancer. Geburtshilfe Frauenheilkd 2018; 78:927-948.
19.10.2018Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032/045OL, December 2017) - Part 1 with Recommendations for the Screening, Diagnosis and Therapy of Breast Cancer
19.10.2018Geburtshilfe Frauenheilkd 2018; 78:927-948
Bjelic-Radisic Vesna, Dunst Jürgen, Münstedt Karsten, Bick Ulrich, Fallenberg Eva, Tholen Reina, Hung Roswita, Baumann Freerk, Beckmann Matthias W, Blohmer Jens, Sinn Hans-Peter, Hirsmüller Susanne, Tesch Hans, Degenhardt Friedrich, Wenz Frederik, Rick Oliver, Hölzel Dieter, Zaiss Matthias, Kemper Gudrun, Budach Volker, Denkert Carsten, Gerber Bernd, Fasching Peter A, Lux Michael P, Harbeck Nadia, Schmidt Marcus, Schmutzler Rita, Schneeweiss Andreas, Schütz Florian, Stickeler Elmar, Thomssen Christoph, Untch Michael, Wesselmann Simone, Bücker Arno, Nöthlings Ute, Müller Volkmar, Möbus Volker, Hadji Peyman, Hauner Hans, Heywang-Köbrunner Sylvia, Huober Jens, Hübner Jutta, Jackisch Christian, Loibl Sibylle, Lück Hans-Jürgen, von Minckwitz Gunter, Krockenberger Mathias, Wöckel Achim, Langer Thomas, Nothacker Monika, Scharl Anton, Schreer Ingrid, Link Hartmut, Engel Jutta, Fehm Tanja, Weis Joachim, Welt Anja, Kühn Thorsten, Kreienberg Rolf, Kopp Ina, Festl Jasmin, Stüber Tanja, Brust Katharina, Stangl Stephanie, Heuschmann Peter U, Albert Ute-Susann, Budach Wilfried, Follmann Markus, Janni Wolfgang, Steckelberg Anke, Feyer Petra, König Klaus, Schulz-Wendtland Rüdiger, Hahn Markus, Hanf Volker, Müller-Schimpfle Markus, Henscher Ulla, Roncarati Renza, Katalinic Alexander, Heitmann Christoph, Honegger Christoph, Bartsch Hans Helge, Petersen Cordula, Siedentopf Friederike, Hahne Andrea, Kreipe Hans H, Knoefel Wolfram Trudo, Denkinger Michael, Brucker Sara, Luftner Diana, Kubisch Christian, Gerlach Christina, Lebeau Annette, Paradies Kerstin
Pregnancies during and after trastuzumab and/or lapatinib in patients with human epidermal growth factor receptor 2-positive early breast cancer: Analysis from the NeoALTTO (BIG 1-06) and ALTTO (BIG 2-06) trials
Lambertini M, de Azambuja E, Gelber R, Piccart-Gebhart M, Moreno-Aspitia A, Baselga J, Huober J, Tenglin R, Di Cosimo S, Azim H, Korde L, Schuehly U, Hilbers F, Guillaume S, Campbell C, Martel S, Ignatiadis M. Pregnancies during and after trastuzumab and/or lapatinib in patients with human epidermal growth factor receptor 2-positive early breast cancer: Analysis from the NeoALTTO (BIG 1-06) and ALTTO (BIG 2-06) trials. Cancer 2018; 125:307-316.
18.10.2018Pregnancies during and after trastuzumab and/or lapatinib in patients with human epidermal growth factor receptor 2-positive early breast cancer: Analysis from the NeoALTTO (BIG 1-06) and ALTTO (BIG 2-06) trials
18.10.2018Cancer 2018; 125:307-316
Lambertini Matteo, de Azambuja Evandro, Gelber Richard D, Piccart-Gebhart Martine, Moreno-Aspitia Alvaro, Baselga José, Huober Jens, Tenglin Richard C, Di Cosimo Serena, Azim Hatem A, Korde Larissa, Schuehly Uwe, Hilbers Florentine S, Guillaume Sébastien, Campbell Christine, Martel Samuel, Ignatiadis Michail
BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto Study
Fasching P, Huober J, Liedtke C, Weinshilboum R, Wang L, Ingle J, Müller V, Nekljudova V, Weber K, Rack B, Rübner M, von Minckwitz G, Fehm T, Blohmer J, Costa S, Loibl S, Hu C, Hart S, Shimelis H, Moore R, Schem C, Tesch H, Untch M, Hilfrich J, Rezai M, Gerber B, Couch F. BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto Study. J Clin Oncol 2018; 36:2281-2287.
23.05.2018BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto Study
23.05.2018J Clin Oncol 2018; 36:2281-2287
Fasching Peter A, Huober Jens, Liedtke Cornelia, Weinshilboum Richard M, Wang Liewei, Ingle James N, Müller Volkmar, Nekljudova Valentina, Weber Karsten E, Rack Brigitte, Rübner Matthias, von Minckwitz Gunter, Fehm Tanja, Blohmer Jens-Uwe, Costa Serban Dan, Loibl Sibylle, Hu Chunling, Hart Steven N, Shimelis Hermela, Moore Raymond, Schem Christian, Tesch Hans, Untch Michael, Hilfrich Jörn, Rezai Mahdi, Gerber Bernd, Couch Fergus J
Risk Assessment after Neoadjuvant Chemotherapy in Luminal Breast Cancer Using a Clinicomolecular Predictor
Loibl S, Kronenwett R, von Minckwitz G, Staebler A, Müller V, Darb-Esfahani S, Hartmann A, Furlanetto J, Kümmel S, Pfitzner B, Engels K, Schem C, Marme F, Krappmann K, Huober J, Weber K, Denkert C. Risk Assessment after Neoadjuvant Chemotherapy in Luminal Breast Cancer Using a Clinicomolecular Predictor. Clin Cancer Res 2018; 24:3358-3365.
04.04.2018Risk Assessment after Neoadjuvant Chemotherapy in Luminal Breast Cancer Using a Clinicomolecular Predictor
04.04.2018Clin Cancer Res 2018; 24:3358-3365
Loibl Sibylle, Kronenwett Ralf, von Minckwitz Gunter, Staebler Annette, Müller Volkmar, Darb-Esfahani Silvia, Hartmann Arndt, Furlanetto Jenny, Kümmel Sherko, Pfitzner Berit Maria, Engels Knut, Schem Christian, Marme Frederik, Krappmann Kristin, Huober Jens, Weber Karsten, Denkert Carsten
Survival Analysis After Neoadjuvant Chemotherapy With Trastuzumab or Lapatinib in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the GeparQuinto (G5) Study (GBG 44)
Untch M, Loibl S, Nekljudova V, Fehm T, Hauschild M, Blohmer J, Kunz G, Jackisch C, Solbach C, Huober J, Hanusch C, Eggemann H, Tesch H, Fasching P, Rezai M, Schem C, Gerber B, von Minckwitz G, GBG and the AGO-B Study Group. Survival Analysis After Neoadjuvant Chemotherapy With Trastuzumab or Lapatinib in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the GeparQuinto (G5) Study (GBG 44). J Clin Oncol 2018; 36:1308-1316.
15.03.2018Survival Analysis After Neoadjuvant Chemotherapy With Trastuzumab or Lapatinib in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the GeparQuinto (G5) Study (GBG 44)
15.03.2018J Clin Oncol 2018; 36:1308-1316
Untch Michael, Loibl Sibylle, Nekljudova Valentina, Fehm Tanja, Hauschild Maik, Blohmer Jens-Uwe, Kunz Georg, Jackisch Christian, Solbach Christine, Huober Jens, Hanusch Claus, Eggemann Holm, Tesch Hans, Fasching Peter A, Rezai Mahdi, Schem Christian, Gerber Bernd, von Minckwitz Gunter, GBG and the AGO-B Study Group
Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial
Loibl S, Liu X, Symmans W, Rastogi P, Metzger Filho O, Ponce Lorenzo J, McIntyre K, Wolmark N, Sullivan D, Maag D, von Minckwitz G, Golshan M, Huober J, McKee M, Rugo H, Sikov W, Untch M, O'Shaughnessy J, Geyer C. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. Lancet Oncol 2018; 19:497-509.
28.02.2018Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial
28.02.2018Lancet Oncol 2018; 19:497-509
Loibl Sibylle, Liu Xuan, Symmans W Fraser, Rastogi Priya, Metzger Filho Otto, Ponce Lorenzo Jose J, McIntyre Kristi, Wolmark Norman, Sullivan Danielle, Maag David, von Minckwitz Gunter, Golshan Mehra, Huober Jens, McKee Mark D, Rugo Hope S, Sikov William M, Untch Michael, O'Shaughnessy Joyce, Geyer Charles E
Ten-year results of intense dose-dense chemotherapy show superior survival compared with a conventional schedule in high-risk primary breast cancer: final results of AGO phase III iddEPC trial
Möbus V, Kurbacher C, Untch M, Konecny G, Hinke A, Runnebaum I, von Minckwitz G, Harbeck N, Huober J, Schneeweiss A, Nitz U, Kuhn W, Thomssen C, du Bois A, Lück H, Jackisch C, AGO Breast Study Group (AGO-B). Ten-year results of intense dose-dense chemotherapy show superior survival compared with a conventional schedule in high-risk primary breast cancer: final results of AGO phase III iddEPC trial. Ann Oncol 2018; 29:178-185.
01.01.2018Ten-year results of intense dose-dense chemotherapy show superior survival compared with a conventional schedule in high-risk primary breast cancer: final results of AGO phase III iddEPC trial
01.01.2018Ann Oncol 2018; 29:178-185
Möbus V, Kurbacher C, Untch M, Konecny G E, Hinke A, Runnebaum I B, von Minckwitz G, Harbeck N, Huober Jens, Schneeweiss A, Nitz U, Kuhn W, Thomssen C, du Bois A, Lück H J, Jackisch C, AGO Breast Study Group (AGO-B)
Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2-positive early-stage breast cancer: a NeoALTTO sub-study (BIG 1-06)
Ponde N, Maetens M, Harbeck N, Pusztai L, Berghorn M, Im Y, Borrego M, Chen D, Rodeheffer R, Piccart M, Suter T, Bozovic-Spasojevic I, Fumagalli D, Bradbury I, Lambertini M, Ewer M, Campbell C, Ameels H, Zardavas D, Di Cosimo S, Baselga J, Huober J, Izquierdo M, de Azambuja E. Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2-positive early-stage breast cancer: a NeoALTTO sub-study (BIG 1-06). Breast Cancer Res Treat 2017; 168:631-638.
27.12.2017Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2-positive early-stage breast cancer: a NeoALTTO sub-study (BIG 1-06)
27.12.2017Breast Cancer Res Treat 2017; 168:631-638
Ponde Noam, Maetens Marion, Harbeck Nadia, Pusztai Lajos, Berghorn Michael, Im Young-Hyuck, Borrego Manuel Ruiz, Chen Dar-Ren, Rodeheffer Richard, Piccart Martine, Suter Thomas, Bozovic-Spasojevic Ivana, Fumagalli Debora, Bradbury Ian, Lambertini Matteo, Ewer Michael, Campbell Christine, Ameels Helene, Zardavas Dimitrios, Di Cosimo Serena, Baselga José, Huober Jens, Izquierdo Miguel, de Azambuja Evandro
Circulating Tumour Cells, Circulating Tumour DNA and Circulating MicroRNA in Metastatic Breast Carcinoma - What is the Role of Liquid Biopsy in Breast Cancer?
Polasik A, Janni W, Huober J, Müller V, Schneeweiss A, Fasching P, Hartkopf A, Rack B, Friedl T, De Gregorio A, Schochter F, Tzschaschel M, Fehm T. Circulating Tumour Cells, Circulating Tumour DNA and Circulating MicroRNA in Metastatic Breast Carcinoma - What is the Role of Liquid Biopsy in Breast Cancer?. Geburtshilfe Frauenheilkd 2017; 77:1291-1298.
18.12.2017Circulating Tumour Cells, Circulating Tumour DNA and Circulating MicroRNA in Metastatic Breast Carcinoma - What is the Role of Liquid Biopsy in Breast Cancer?
18.12.2017Geburtshilfe Frauenheilkd 2017; 77:1291-1298
Polasik Arkadius, Janni Wolfgang, Huober Jens, Müller Volkmar, Schneeweiss Andreas, Fasching Peter A, Hartkopf Andreas, Rack Brigitte, Friedl Thomas W P, De Gregorio Amelie, Schochter Fabienne, Tzschaschel Marie, Fehm Tanja
Update Breast Cancer 2017 - Implementation of Novel Therapies
Lux M, Wallwiener M, Müller V, Beckmann M, Belleville E, Fehm T, Wallwiener D, Brucker S, Schneeweiss A, Luftner D, Huober J, Ettl J, Janni W, Hartkopf A, Nabieva N, Taran F, Overkamp F, Kolberg H, Hadji P, Tesch H, Fasching P. Update Breast Cancer 2017 - Implementation of Novel Therapies. Geburtshilfe Frauenheilkd 2017; 77:1281-1290.
18.12.2017Update Breast Cancer 2017 - Implementation of Novel Therapies
18.12.2017Geburtshilfe Frauenheilkd 2017; 77:1281-1290
Lux Michael P, Wallwiener Markus, Müller Volkmar, Beckmann Matthias W, Belleville Erik, Fehm Tanja N, Wallwiener Diethelm, Brucker Sara Y, Schneeweiss Andreas, Luftner Diana, Huober Jens, Ettl Johannes, Janni Wolfgang, Hartkopf Andreas D, Nabieva Naiba, Taran Florin-Andrei, Overkamp Friedrich, Kolberg Hans-Christian, Hadji Peyman, Tesch Hans, Fasching Peter A
The use of breast imaging for predicting response to neoadjuvant lapatinib, trastuzumab and their combination in HER2-positive breast cancer: Results from Neo-ALTTO
Di Cosimo S, Ng W, Colleoni M, Ferro A, Naume B, Patel A, Huober J, Piccart-Gebhart M, Baselga J, Vinholes J, Fein L, Fumagalli D, Campbell C, Azim H, Galli G, Bregni G, Curigliano G, Criscitiello C, Izquierdo M, de la Pena L, De Azambuja E. The use of breast imaging for predicting response to neoadjuvant lapatinib, trastuzumab and their combination in HER2-positive breast cancer: Results from Neo-ALTTO. Eur J Cancer 2017; 89:42-48.
08.12.2017The use of breast imaging for predicting response to neoadjuvant lapatinib, trastuzumab and their combination in HER2-positive breast cancer: Results from Neo-ALTTO
08.12.2017Eur J Cancer 2017; 89:42-48
Di Cosimo S, Ng W M J, Colleoni M, Ferro A, Naume B J, Patel A, Huober Jens, Piccart-Gebhart M J, Baselga J, Vinholes J, Fein L, Fumagalli D, Campbell C, Azim H A, Galli G, Bregni G, Curigliano G, Criscitiello C, Izquierdo M, de la Pena L, De Azambuja E
Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy
Denkert C, Engels K, Schneeweiss A, Hartmann A, Noske A, Fasching P, Jackisch C, van Mackelenbergh M, Sinn P, Schem C, Hanusch C, Untch M, Kümmel S, Pfitzner B, Karn T, von Minckwitz G, Darb-Esfahani S, Lederer B, Heppner B, Weber K, Budczies J, Huober J, Klauschen F, Furlanetto J, Schmitt W, Blohmer J, Loibl S. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol 2017; 19:40-50.
07.12.2017Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy
07.12.2017Lancet Oncol 2017; 19:40-50
Denkert Carsten, Engels Knut, Schneeweiss Andreas, Hartmann Arndt, Noske Aurelia, Fasching Peter A, Jackisch Christian, van Mackelenbergh Marion, Sinn Peter, Schem Christian, Hanusch Claus, Untch Michael, Kümmel Sherko, Pfitzner Berit M, Karn Thomas, von Minckwitz Gunter, Darb-Esfahani Silvia, Lederer Bianca, Heppner Barbara I, Weber Karsten E, Budczies Jan, Huober Jens, Klauschen Frederick, Furlanetto Jenny, Schmitt Wolfgang D, Blohmer Jens-Uwe, Loibl Sibylle
Expression of Cyclin D1 protein in residual tumor after neoadjuvant chemotherapy for breast cancer
Villegas S, Denkert C, Mehta K, Müller V, Kümmel S, Engels K, Lederer B, Pfitzner B, Schem C, Furlanetto J, Marmé F, Weber K, Huober J, von Minckwitz G, Darb-Esfahani S, Loibl S. Expression of Cyclin D1 protein in residual tumor after neoadjuvant chemotherapy for breast cancer. Breast Cancer Res Treat 2017; 168:179-187.
25.11.2017Expression of Cyclin D1 protein in residual tumor after neoadjuvant chemotherapy for breast cancer
25.11.2017Breast Cancer Res Treat 2017; 168:179-187
Villegas S L, Denkert C, Mehta K, Müller V, Kümmel S, Engels K, Lederer B, Pfitzner B M, Schem C, Furlanetto J, Marmé F, Weber K, Huober Jens, von Minckwitz G, Darb-Esfahani S, Loibl S
Discordance in Human Epidermal Growth Factor Receptor 2 (HER2) Phenotype Between Primary Tumor and Circulating Tumor Cells in Women With HER2-Negative Metastatic Breast Cancer
De Gregorio A, Janni W, Fasching P, Taran F, Hartkopf A, Jaeger B, Meier-Stiegen F, Pantel K, Schneeweiss A, Mueller V, Riethdorf S, Alunni-Fabbroni M, Trapp E, Rack B, De Gregorio N, Scholz C, Huober J, Friedl T, Fehm T. Discordance in Human Epidermal Growth Factor Receptor 2 (HER2) Phenotype Between Primary Tumor and Circulating Tumor Cells in Women With HER2-Negative Metastatic Breast Cancer. JCO Precis Oncol 2017; 1:1-12.
01.11.2017Discordance in Human Epidermal Growth Factor Receptor 2 (HER2) Phenotype Between Primary Tumor and Circulating Tumor Cells in Women With HER2-Negative Metastatic Breast Cancer
01.11.2017JCO Precis Oncol 2017; 1:1-12
De Gregorio Amelie, Janni Wolfgang, Fasching Peter A, Taran Florin-Andrei, Hartkopf Andreas, Jaeger Bernadette, Meier-Stiegen Franziska, Pantel Klaus, Schneeweiss Andreas, Mueller Volkmar, Riethdorf Sabine, Alunni-Fabbroni Marianna, Trapp Elisabeth, Rack Brigitte, De Gregorio Nikolaus, Scholz Christoph, Huober Jens, Friedl Thomas W P, Fehm Tanja
Treatment landscape of advanced breast cancer patients with hormone receptor positive HER2 negative tumors - Data from the German PRAEGNANT breast cancer registry
Hartkopf A, Wimberger P, Hielscher C, Geberth M, Fersis N, Abenhardt W, Kurbacher C, Wuerstlein R, Thomssen C, Untch M, Fasching P, Janni W, Fehm T, Wallwiener D, Brucker S, Belleville E, Beckmann M, Müller V, Huober J, Volz B, Nabieva N, Taran F, Schwitulla J, Overkamp F, Kolberg H, Hadji P, Tesch H, Häberle L, Ettl J, Lux M, Luftner D, Wallwiener M, Schneeweiss A. Treatment landscape of advanced breast cancer patients with hormone receptor positive HER2 negative tumors - Data from the German PRAEGNANT breast cancer registry. Breast 2017; 37:42-51.
26.10.2017Treatment landscape of advanced breast cancer patients with hormone receptor positive HER2 negative tumors - Data from the German PRAEGNANT breast cancer registry
26.10.2017Breast 2017; 37:42-51
Hartkopf Andreas D, Wimberger Pauline, Hielscher Carsten, Geberth Matthias, Fersis Nikos, Abenhardt Wolfgang, Kurbacher Christian, Wuerstlein Rachel, Thomssen Christoph, Untch Michael, Fasching Peter A, Janni Wolfgang, Fehm Tanja N, Wallwiener Diethelm, Brucker Sara Y, Belleville Erik, Beckmann Matthias W, Müller Volkmar, Huober Jens, Volz Bernhard, Nabieva Naiba, Taran Florin-Andrei, Schwitulla Judith, Overkamp Friedrich, Kolberg Hans-Christian, Hadji Peyman, Tesch Hans, Häberle Lothar, Ettl Johannes, Lux Michael P, Luftner Diana, Wallwiener Markus, Schneeweiss Andreas